 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: Approved HIV reverse transcriptase inhibitors in the past decade. (Pubmed Central) - Jul 20, 2022
Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains.
- MK-8504 / Merck (MSD), MK-8583 / Merck (MSD)
[VIRTUAL] MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_375;
The persistent adequate concentrations of TFV-DP belie the poor VL response; it is possible, though, that VL responses could improve with daily administration of MK-8504 or MK-8583. Collectively, these data raise questions about the feasibility of TFV prodrugs in extended-interval dosing regimens.
- MK-8504 / Merck (MSD), MK-8583 / Merck (MSD)
MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV INFECTION (Ballroom B) - Mar 2, 2020 - Abstract #CROI2020CROI_374;
- | MK-8583 / Merck (MSD)
Trial completion, Enrollment change, Monotherapy: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) (clinicaltrials.gov) - Mar 25, 2019
P1, N=5, Completed, Sponsor: Merck Sharp & Dohme Corp.
Collectively, these data raise questions about the feasibility of TFV prodrugs in extended-interval dosing regimens. Active, not recruiting --> Completed | N=18 --> 5
- | MK-8583 / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) (clinicaltrials.gov) - Feb 28, 2019
P1, N=18, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=18 --> 5 Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Mar 2019 | Trial primary completion date: Aug 2019 --> Mar 2019
- | MK-8583 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) (clinicaltrials.gov) - Feb 15, 2019
P1, N=18, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Mar 2019 | Trial primary completion date: Aug 2019 --> Mar 2019 Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019
- | MK-8583 / Merck (MSD)
Enrollment open, Monotherapy: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) (clinicaltrials.gov) - Oct 18, 2018
P1, N=18, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019 Not yet recruiting --> Recruiting
- || MK-8583 / Merck (MSD)
New P1 trial, Monotherapy: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) (clinicaltrials.gov) - Jun 12, 2018
P1, N=18, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.